Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Pharmaceutical Market: Mexico
Management Report
Published: January 2010
Pages: 87
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
MEXICO - MARKET REVIEW
The exchange rate of the Mexican peso against the US dollar is causing uncertainty, with increasing pharmaceutical import costs. Growth in the private pharmacy sector is expected to be moderate in the next few years. Pfizer’s acquisition of Wyeth and the merger of Merck Sharp & Dohme with Schering Plough will change the sector, with sanofi-aventis being pushed down. In spite of moderate growth, the sector will continue to offer long-term opportunities. Takeda is one of the latest multinational producers to establish a subsidiary in Mexico.
On a positive note, the downturn is fuelling generics consumption. This market, which relies on public sales rather than private pharmacy sales, is expected to double in size in 2010. As a result, a number of foreign producers are strengthening their operations in the country, mainly via acquisitions. Valeant, for instance, acquired a local producer in July 2009. Previously, sanofi-aventis acquired another local producer in the first half of 2009. Local competition is also increasing. Genomma Lab, for instance, launched its generic product portfolio in August 2009, directly competing with members of ANAFAM.
In September 2009, the reform of the LGS that will allow the sale and production of biologic and ‘biocomparable’ medicines in Mexico was enforced; the reform was published in June 2009. Article 222 Bis defines and regulates biologic and biosimilar medicines, including the requirements to register and market these medicines. The new regulation represents sizeable opportunities for both local and foreign producers. Local producers such as Probiomed, Silanes and Landsteiner Scientific already produce biologic medicines in Mexico. Competition, however, is expected to arise from foreign producers. On a patient level, the new regulation provides product safety and availability.
Local manufacturing plant requirements are being phased out over a two-year period. Competition from foreign producers is going to increase, particularly from those which until now did not have the resources to establish manufacturing facilities in Mexico. Imports of antiretrovirals were released in August 2008. Imports of vitamins, homeopathic medicines, vaccines, sera, haemoderivatives, antitoxins and biologic hormones were released in February 2009. Producers of other biologics such as insulin and erythropoietin have been able to export to Mexico since August 2009. The liberation for narcotic or psychotropic drugs and OTC drugs will happen in February 2010. Finally, the market will be fully open by mid 2010.
The reform of the Health Supplies Regulation, published in the Official Bulletin in January 2008, has ‘improved’ the renewal and registration processes of pharmaceuticals, and there will only be patented and bioequivalent generic drugs in the market from 24th February 2010. Of the 10,500 pharmaceuticals whose registrations need to be renewed, the Federal National Commission for Protection against Health Risks (COFEPRIS) estimates that about 17% will exit the market. Many local producers believe that this is a frontal attack against the local pharmaceutical industry. By mid 2009, COFEPRIS indicated that nearly three quarters of the registrations were in process; it believes completion will be on time.
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
MEXICO - MARKET REVIEW
The exchange rate of the Mexican peso against the US dollar is causing uncertainty, with increasing pharmaceutical import costs. Growth in the private pharmacy sector is expected to be moderate in the next few years. Pfizer’s acquisition of Wyeth and the merger of Merck Sharp & Dohme with Schering Plough will change the sector, with sanofi-aventis being pushed down. In spite of moderate growth, the sector will continue to offer long-term opportunities. Takeda is one of the latest multinational producers to establish a subsidiary in Mexico.
On a positive note, the downturn is fuelling generics consumption. This market, which relies on public sales rather than private pharmacy sales, is expected to double in size in 2010. As a result, a number of foreign producers are strengthening their operations in the country, mainly via acquisitions. Valeant, for instance, acquired a local producer in July 2009. Previously, sanofi-aventis acquired another local producer in the first half of 2009. Local competition is also increasing. Genomma Lab, for instance, launched its generic product portfolio in August 2009, directly competing with members of ANAFAM.
In September 2009, the reform of the LGS that will allow the sale and production of biologic and ‘biocomparable’ medicines in Mexico was enforced; the reform was published in June 2009. Article 222 Bis defines and regulates biologic and biosimilar medicines, including the requirements to register and market these medicines. The new regulation represents sizeable opportunities for both local and foreign producers. Local producers such as Probiomed, Silanes and Landsteiner Scientific already produce biologic medicines in Mexico. Competition, however, is expected to arise from foreign producers. On a patient level, the new regulation provides product safety and availability.
Local manufacturing plant requirements are being phased out over a two-year period. Competition from foreign producers is going to increase, particularly from those which until now did not have the resources to establish manufacturing facilities in Mexico. Imports of antiretrovirals were released in August 2008. Imports of vitamins, homeopathic medicines, vaccines, sera, haemoderivatives, antitoxins and biologic hormones were released in February 2009. Producers of other biologics such as insulin and erythropoietin have been able to export to Mexico since August 2009. The liberation for narcotic or psychotropic drugs and OTC drugs will happen in February 2010. Finally, the market will be fully open by mid 2010.
The reform of the Health Supplies Regulation, published in the Official Bulletin in January 2008, has ‘improved’ the renewal and registration processes of pharmaceuticals, and there will only be patented and bioequivalent generic drugs in the market from 24th February 2010. Of the 10,500 pharmaceuticals whose registrations need to be renewed, the Federal National Commission for Protection against Health Risks (COFEPRIS) estimates that about 17% will exit the market. Many local producers believe that this is a frontal attack against the local pharmaceutical industry. By mid 2009, COFEPRIS indicated that nearly three quarters of the registrations were in process; it believes completion will be on time.